Status:
COMPLETED
The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI
Lead Sponsor:
Emory University
Collaborating Sponsors:
Siemens Medical Solutions
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fra...
Detailed Description
Participants will be patients who are scheduled to undergo PET Myocardial Perfusion Imaging, which is the traditional method for evaluating patients with suspected blockages or narrowing of the heart ...
Eligibility Criteria
Inclusion
- Referred for a clinically indicated CT-MPI for CAD assessment
- Must provide written informed consent prior to any study-related procedures being performed
- Must be willing to comply with all clinical study procedures
Exclusion
- Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post-menopausal, with minimum one (1) year history without menses.
- Currently taking or has taken within 48 hours the following excluded medications:
- ActoPlus Met (Pioglitazone + metformin)
- Avandamet (Rosiglitazone + metformin)
- Fortamet (metformin)
- Glucovance (Glyburide +metformin)
- Glucophage (metformin)
- Glucophage extended-release (XR) (metformin)
- Glumetza (metformin)
- Janumet (Sitagliptin + metformin)
- Metformin
- Metaglip (Glipizide + metformin)
- Riomet (metformin)
- Acute psychiatric disorder
- Unwilling to comply with the requirements of the protocol
- Previously entered this study
- Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study
- Suffers from claustrophobia
- Impaired renal function (GFR \< 45 ml/min)
- Acute hypotension (\<100 mm Hg systolic)
- 2nd or 3rd degree atrioventricular (AV) block
Key Trial Info
Start Date :
June 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04316676
Start Date
June 16 2021
End Date
September 24 2024
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Hospital
Atlanta, Georgia, United States, 30322